Therapeutic vaccines against HIV infection

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 5, 2012, Pages 569-581

  García, Felipe ^a   León, Agathe ^a   Gatell, Josep M ^a   Plana, Montserrat ^a   Gallart, Teresa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dendritic cell; DNA; Functional cure; HIV; Recombinant virus; Therapeutic vaccine

Indexed keywords

CP1433; CP1452; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; LIPO 6T VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; PLACEBO; RECOMBINANT ADENOVIRUS SEROTYPE 5 HUMAN IMMUNODEFICIENCY VIRUS 1 GAG VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; REVIEW; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VACCINATION;

EID: 84863705453     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19555     Document Type: Review

References (172)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. In: 1998. pp. 853-860.
2. Montaner JS. Treatment as prevention-a double hattrick. Lancet 2011; 378:208-9; PMID:21763923; http://dx.doi.org/10.1016/S0140-6736(11)60821-0
3. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-9; PMID:20638713; http://dx.doi.org/10.1016/S0140-6736(10)60936-1
4. Martinez E,Mocroft A, García-Viejo M, Pérez-Cuevas J, Blanco J, Mallolas J, et al. A prospective cohort study on the risk for lipodystrophy in HIV-1 infected patients treated with protease inhibitor-containing regimens. Lancet 2001; 357:592-8; PMID:11558485; http://dx.doi.org/10.1016/S0140-6736(00)04056-3
5. Sidibé M. Newsmaker interview: Michel Sidibé. New HIV infections drop, but treatment demands rise. Interview by Jon Cohen. [Abstract]. Science 2010; 330:1301; PMID:21127221
6. García F, Ruiz L, Lopez-Bernaldo de Quirós J, Moreno S, Domingo P. INMUNOTERAPIA Y VACUNAS TERAPEUTICAS EN LA INFECCIÓN POR VIH. Enf Inf Microb Clin 2005; 23(Suppl 2):84-94; http://dx.doi.org/10.1016/S0213- 005X(05)75164-8
7. Cohen J. The emerging race to cure HIV infections. Science 2011; 332:784-5, 787-9; PMID:21566173; http://dx.doi.org/10.1126/science.332.6031.784
8. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-8; PMID:19213682; http://dx.doi.org/10.1056/NEJMoa0802905
9. Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood 2011; 117:2791-9; PMID:21148083; http://dx.doi.org/10. 1182/blood-2010-09-309591
10. Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. NatMed 2010; 16:460-5; PMID:20228817; http://dx.doi.org/10.1038/nm.2111
11. Kambal A, Mitchell G, Cary W, Gruenloh W, Jung Y, Kalomoiris S, et al. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther 2011; 19:584-93; PMID:21119622; http://dx.doi.org/10.1038/mt.2010.269
12. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901-6; PMID:19448633; http://dx.doi.org/10.1038/nm.1967
13. McMichael AJ, Jones EY. Genetics. First-class control of HIV-1. Science 2010; 330:1488-90; PMID:21148380; http://dx.doi.org/10.1126/science.1200035
14. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al & International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-7; PMID:21051598; http://dx.doi.org/10.1126/science.1195271
15. Autran B, Carcelain G. AIDS. Boosting immunity to HIV-can the virus help? Science 2000; 290:946-9; PMID:11184735; http://dx.doi.org/10.1126/science.290. 5493.946
16. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305:205-8; PMID:15247470; http://dx.doi.org/ 10.1126/science.1100600
17. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 2003; 9:861-6; PMID:12835706; http://dx.doi.org/10.1038/ nm0703-861
18. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93; PMID:22217938; http://dx.doi.org/10. 1038/nature10766
19. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-7; PMID:21562493; http://dx.doi.org/10.1038/ nature10003
20. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. [see comments]. Science 1997; 278:1447-50; PMID:9367954; http://dx.doi.org/10.1126/science.278.5342.1447
21. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6; PMID:11029005; http://dx.doi.org/10.1038/35035103
22. Moore JP, Cao Y, Ho DD, Koup RA. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68:5142-55; PMID:8035514
23. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-7; PMID: 15793563; http://dx.doi.org/10.1038/nature03501
24. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-8; PMID:11986671; http://dx.doi.org/10.1038/417095a
25. Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, Clotet B, et al & ORVACS Study Group. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011; 25:27-36; PMID:21076273; http://dx.doi.org/10.1097/QAD. 0b013e328340fe55
26. Schmitz JE, Kuroda MJ, Santra S. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. In: 1999. pp. 857-860.
27. Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, Di Mascio M, et al. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med 2000; 191:1921-31; PMID:10839807; http://dx.doi.org/10.1084/ jem.191.11.1921
28. de Quiros JC, Shupert WL, McNeil AC, Gea-Banacloche JC, Flanigan M, Savage A, et al. Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen. J Virol 2000; 74:2023-8; PMID:10644376; http://dx.doi.org/10.1128/JVI.74.4.2023-2028.2000
29. Day CL, Walker BD. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003; 198:1773-7; PMID:14676292; http://dx.doi.org/10.1084/jem.20031947
30. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific preand postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002; 169:4778-87; PMID:12391187
31. Kaech SM, Ahmed R. Immunology. CD8 T cells remember with a little help. Science 2003; 300:263-5; PMID:12690179; http://dx.doi.org/10.1126/science. 1084511
32. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 2003; 100:15131-6; PMID:14627745; http://dx.doi.org/10.1073/pnas.2436476100
33. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-9; PMID:12644702; http://dx.doi.org/10.1073/pnas.0630530100
34. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, Buchbinder S, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11:1290-2; PMID:16288280; http://dx.doi.org/10.1038/nm1333
35. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'sullivan KM, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79:13239-49; PMID:16227247; http://dx.doi.org/10.1128/JVI.79.21.13239-13249.2005
36. Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, et al. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005; 79:12952-60; PMID:16188997; http://dx.doi.org/10.1128/ JVI.79.20.12952-12960.2005
37. Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, et al. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol 2005; 174:7524-30; PMID:15944251
38. Altfeld M, Allen TM, Kalife ET, Frahm N, Addo MM, Mothe BR, et al. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design. J Virol 2005; 79:5000-5; PMID:15795285; http://dx.doi.org/10.1128/JVI.79.8.5000- 5005.2005
39. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004; 78:7069-78; PMID:15194783; http://dx.doi.org/10.1128/JVI.78.13. 7069-7078.2004
40. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C, et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004; 199:905-15; PMID:15067030; http://dx.doi.org/10.1084/jem.20031982
41. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282-9; PMID:14770175; http://dx.doi.org/10.1038/nm992
42. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412:334-8; PMID:11460164; http://dx.doi.org/10.1038/35085576
43. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282-9; PMID:14770175; http://dx.doi.org/10.1038/nm992
44. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4+ Tcells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:518-25; PMID: 10229228; http://dx.doi.org/10.1038/8400
45. Plana M, Garcia F, Gallart MT, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet 1998; 352:1194-5; PMID:9777842; http://dx. doi.org/10.1016/S0140-6736(05)60532-6
46. Yokomaku Y, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, Kojima A, et al. Impaired processing and presentation of CTL epitopes are major escape mechanisms from CTL immune pressure in Human Immunodeficiency Virus type 1 infection. J Virol 2004; 78:1324-32; PMID:14722287; http://dx.doi.org/10.1128/ JVI.78.3.1324-1332.2004
47. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003; 4:835-42; PMID: 12942084; http://dx.doi.org/10.1038/ni969
48. Yang OO, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol 2003; 171:3718-24; PMID:14500671
49. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003; 101:4505-11; PMID:12576311; http://dx.doi.org/10.1182/blood-2002-10-3189
50. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002; 168:4796-801; PMID: 11971031
51. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, Davey RT, Jr., et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A 2001; 98:13878-83; PMID:11717444; http://dx.doi.org/10.1073/pnas.251539598
52. McKay PF, Barouch DH, Schmitz JE, Veazey RS, Gorgone DA, Lifton MA, et al. Global dysfunction of CD4 T-lymphocyte cytokine expression in simianhuman immunodeficiency virus/SIV-infected monkeys is prevented by vaccination. J Virol 2003; 77:4695-702; PMID:12663776; http://dx.doi.org/10.1128/JVI.77.8.4695-4702. 2003
53. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. [see comments]. Science 1997; 277:112-6; PMID:9204894; http://dx.doi.org/10.1126/science.277.5322.112
54. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-6; PMID:8599114; http://dx.doi.org/10.1126/science. 271.5255.1582
55. Perelson AS, Essunger P, Cao Y. Decay characteristics of HIV-1 infected compartments during combination therapy. In: 1997. pp. 188-191.
56. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7; PMID: 10229227; http://dx.doi.org/10.1038/8394
57. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-93; PMID:11818490; http://dx.doi.org/10.1146/annurev.med.53.082901.104024
58. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-13; PMID:10341272; http://dx.doi.org/10.1056/NEJM199905273402101
59. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. [see comments]. N Engl J Med 1999; 340:1614-22; PMID:10341273; http://dx.doi.org/10.1056/NEJM199905273402102
60. Gamberg J, Barrett L, Bowmer MI, Howley C, Grant M. Factors related to loss of HIV-specific cytotoxic T lymphocyte activity. AIDS 2004; 18:597-604; PMID: 15090764; http://dx.doi.org/10.1097/00002030-200403050-00003
61. Lange CG, Xu Z, Patterson BK, Medvik K, Harnisch B, Asaad R, et al. Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS 2004; 18: 605-13; PMID:15090765; http://dx.doi.org/10.1097/00002030-200403050-00004
62. García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79-86; PMID: 10449278; http://dx.doi.org/10.1097/00002030-199907300-00002
63. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. [Abstract 354 ] [Abstract]. AIDS 2000; 14:397-403; PMID:10770542; http://dx.doi.org/10.1097/00002030-200003100-00013
64. Plana M, García F, Gallart T, Tortajada C, Soriano A, Palou E, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000; 14:1921-33; PMID: 10997396; http://dx.doi.org/10.1097/00002030-200009080-00007
65. Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, et al & EuroSIDA in EuroCoord. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS 2011; 25:2259-68; PMID:21918422; http://dx.doi.org/10.1097/QAD. 0b013e32834cdb4b
66. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al & EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-70; PMID:20700060; http://dx.doi.org/10.1097/QAI.0b013e3181e9be6b
67. Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, et al & Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376:340-5; PMID:20638118; http://dx.doi.org/10.1016/S0140-6736(10)60932-4
68. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al & NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26; PMID:19339714; http://dx.doi.org/10.1056/NEJMoa0807252
69. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al & Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96; PMID:17135583; http://dx.doi.org/10.1056/NEJMoa062360
70. Kahn JO, Walker BD. Current concepts: acute human immunodeficiency virus type 1 infection. In: 1998. pp. 33-39.
71. Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, et al. CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 158-62; PMID:9052725; http://dx.doi.org/10.1097/00042560-199702010-00009
72. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996; 10:827-34; PMID:8828739; http://dx.doi.org/10.1097/00002030-199607000-00005
73. Diaz A, García F, Mozos A, Caballero M, León A, Martinez A, et al. Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors. J Infect Dis 2011; 203:810-3; PMID:21343147; http://dx.doi.org/10.1093/infdis/ jiq129
74. Diaz A, Alós L, León A, Mozos A, Caballero M, Martinez A, et al & Study Group of Lymphoid Tissue immunopathogenesis in HIV infection. Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. AIDS 2010; 24:2029-39; PMID:20588162; http://dx.doi.org/10.1097/QAD.0b013e32833c3268
75. Garrido M, Mozos A, Martínez A, García F, Serafín A, Morente V, et al.HIV-1 upregulates intercellular adhesion molecule-1 gene expression in lymphoid tissue of patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr 2007; 46:268-74; PMID:17786132; http://dx.doi.org/10.1097/ QAI.0b013e318142c74c
76. Mozos A, Garrido M, Carreras J, Plana M, Diaz A, Alos L, et al. Redistribution of FOXP3-positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-infected patients. J Acquir Immune Defic Syndr 2007; 46:529-37; PMID:18193494; http://dx.doi.org/10.1097/QAI.0b013e31815b69ae
77. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-43; PMID:12195350; http://dx.doi.org/10. 1086/342559
78. MacGregor RR, Ginsberg R, Ugen KE, Baine Y, Kang CU, Tu XM, et al. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS 2002; 16:2137-43; PMID:12409734; http://dx.doi.org/10.1097/00002030-200211080-00005
79. MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis 2000; 181:406; PMID: 10608800; http://dx.doi.org/10.1086/315199
80. Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis 2000; 182:1357-64; PMID:11023459; http://dx.doi.org/ 10.1086/315860
81. Smith D, Gow I, Colebunders R, Weller I, Tchamouroff S, Weber J, et al & 006 Study Group. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med 2001; 2:272-5; PMID:11737409; http://dx.doi.org/10.1046/j.1468-1293. 2001.00080.x
82. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10(Suppl 2):S74-82; PMID:7552517
83. Eron JJ, Jr., Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996; 348:1547-51; PMID:8950881; http://dx.doi.org/10.1016/S0140-6736(96) 05283-X
84. Sandström E, Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999; 353: 1735-42; PMID:10347985; http://dx.doi.org/10.1016/S0140-6736(98)06493-9
85. Peters BS, Cheingsong-Popov R, Callow D, Foxall R, Patou G, Hodgkin K, et al. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J Infect 1997; 35:231-5; PMID:9459393; http://dx.doi.org/10.1016/S0163-4453(97)92814-0
86. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178:92-100; PMID: 9652427
87. Robbins GK, Addo MM, Troung H, Rathod A, Habeeb K, Davis B, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 2003; 17:1121-6; PMID:12819512; http://dx.doi.org/10.1097/00002030-200305230-00002
88. LedermanMM, Douek DC. Sometimes help may not be enough. AIDS 2003; 17:1249-51; PMID:12819528; http://dx.doi.org/10.1097/00002030-200305230-00018
89. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 2000; 284:2193-202; PMID:11056590; http://dx.doi.org/10.1001/jama.284.17.2193
90. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004; 200:701-12; PMID:15381726; http://dx.doi.org/10.1084/jem.20041270
91. Gorse GJ, Simionescu RE, Patel GB. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1. Clin Vaccine Immunol 2006; 13:26-32; PMID:16425996; http://dx.doi.org/10.1128/CVI.13.1.26-32. 2006
92. Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis 2000; 181:881-9; PMID: 10720508; http://dx.doi.org/10.1086/315308
93. Eron JJ, Jr., Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996; 348:1547-51; PMID:8950881; http://dx.doi.org/10.1016/S0140-6736(96) 05283-X
94. Pontesilli O, Guerra EC, Ammassari A, Tomino C, Carlesimo M, Antinori A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS 1998; 12:473-80; PMID:9543445; http://dx.doi.org/10. 1097/00002030-199805000-00008
95. Sitz KV, Ratto-Kim S, Hodgkins AS, Robb ML, Birx DL. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. J Infect Dis 1999; 179:817-24; PMID: 10068576; http://dx.doi.org/10.1086/314685
96. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, et al & Military Medical Consortium for Applied Retroviral Research. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991; 324:1677-84; PMID:1674589; http://dx.doi.org/10.1056/ NEJM199106133242401
97. Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis 2000; 182:1357-64; PMID:11023459; http://dx.doi.org/ 10.1086/315860
98. Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, et al. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996; 173:1336-46; PMID:8648205; http://dx.doi.org/10.1093/infdis/ 173.6.1336
99. Wahren B, Bratt G, Persson C, Levén B, Hinkula J, Gilljam G, et al. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994; 7:220-9; PMID: 7906300
100. Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999; 180:1080-8; PMID:10479134; http://dx.doi.org/10.1086/314985
101. Kran AM, Sommerfelt MA, Sørensen B, Nyhus J, Baksaas I, Bruun JN, et al. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005; 23:4011-5; PMID:15963359; http://dx.doi.org/10.1016/j.vaccine.2005.03.010
102. Kran AM, Sørensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006; 20:627-30; PMID:16470131; http://dx.doi.org/10.1097/01.aids.0000210620.75707.ac
103. Kran AM, Sørensen B, Nyhus J, Sommerfelt MA, Baksaas I, Bruun JN, et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004; 18:1875-83; PMID:15353973; http://dx.doi.org/10.1097/00002030-200409240-00003
104. Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010; 5:e13540; PMID:21085635; http://dx.doi.org/10.1371/journal.pone. 0013540
105. Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009; 27:3306-12; PMID:19208456; http://dx.doi.org/10.1016/j.vaccine. 2009.01.090
106. Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 2008; 22:2207-9; PMID:18832884; http://dx.doi.org/10.1097/QAD. 0b013e32831392d4
107. Lichterfeld M, Gandhi RT, Simmons RP, Flynn T, Sbrolla A, Yu XG, et al. Induction of Strong HIV-1-specific CD4+ T Cell Responses using an HIV-1 gp120/NefTat Vaccine adjuvanted with AS02A in ARV Treated HIV-1-Infected Individuals. J Acquir Immune Defic Syndr 2011
108. Cafaro A, Titti F, Fracasso C, MaggiorellaMT, Baroncelli S, Caputo A, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001; 19:2862-77; PMID:11282197; http://dx.doi.org/10.1016/S0264-410X(01)00002-0
109. Allen TM, O'Connor DH, Jing P, Dzuris JL, MothéBR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-90; PMID: 11014195; http://dx.doi.org/10.1038/35036559
110. Fernandez-Cruz E, Moreno S, Navarro J, Clotet B, Bouza E, Carbone J, et al & STIR-2102 TEAM. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004; 22:2966-73; PMID:15297045; http://dx.doi.org/10.1016/j.vaccine.2004.03.040
111. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandström E, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:1320-5; PMID: 9643795; http://dx.doi.org/10.1016/S0140-6736(97)09440-3
112. Hejdeman B, Boström AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, et al. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:860-70; PMID:15320990; http://dx.doi.org/10.1089/0889222041725190
113. MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine 2005; 23:2066-73; PMID: 15755572; http://dx.doi.org/10.1016/j.vaccine.2005.01.010
114. Dorrell L, Yang H, Iversen AK, Conlon C, Suttill A, Lancaster M, et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 2005; 19:1321-3; PMID:16052088; http://dx.doi.org/10.1097/01. aids.0000180104.65640.16
115. Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005; 19:35-43; PMID:15627031; http://dx.doi.org/10.1097/00002030-200501030- 00004
116. Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, et al. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine 2011; 29:5558-66; PMID: 21300092; http://dx.doi.org/10.1016/j. vaccine.2011.01.064
117. Pantaleo G, Esteban M, Jacobs B, Tartaglia J. Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS 2010; 5:391-6; PMID:20978379; http://dx.doi.org/10. 1097/COH.0b013e32833d1e87
118. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schäfer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 1974; 99:2386-92; PMID:4426258; http://dx.doi.org/10.1055/s-0028-1108143
119. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998; 244:365-96; PMID:9601507; http://dx.doi.org/10. 1006/viro.1998.9123
120. Stickl HA. Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine "MVA". Prev Med 1974; 3:97-101; PMID: 4205586; http://dx.doi.org/10.1016/0091-7435(74)90066-8
121. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85:911-9; PMID: 15039533; http://dx.doi.org/10.1099/vir.0.19701-0
122. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006; 24:417-25; PMID:16176847; http://dx.doi.org/10.1016/j.vaccine.2005.08.041
123. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 2006; 80:4717-28; PMID:16641265; http://dx.doi.org/10.1128/JVI.80.10.4717-4728.2006
124. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al & QUEST Study Group. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-17; PMID:16028129; http://dx.doi.org/10. 1086/432002
125. Jin X, Ramanathan M, Jr., Barsoum S, Deschenes GR, Ba L, Binley J, et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002; 76:2206-16; PMID:11836398; http://dx.doi.org/10.1128/jvi.76.5.2206-2216.2002
126. Lévy Y, Gahéry-Ségard H, Durier C, Lascaux AS, Goujard C, Meiffrédy V, et al & ANRS 093 Study Group. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005; 19:279-86; PMID:15718838
127. Johnson DC, McFarland EJ, Muresan P, Fenton T, McNamara J, Read JS, et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis 2005; 192:2129-33; PMID:16288378; http://dx.doi.org/10.1086/498163
128. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, et al & for the Vacciter Study group. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 2005; 23: 4292-301; PMID:15927325; http://dx.doi.org/10.1016/j.vaccine.2005.04.013
129. Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ, Jr., Coombs RW, et al & National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 2006; 194:623-32; PMID:16897661; http://dx.doi.org/10.1086/506364
130. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, et al & ORVACS Study Group. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313-22; PMID:18580611; http://dx.doi.org/10.1097/QAD. 0b013e3282fdce94
131. Angel JB, Routy JP, Tremblay C, Ayers D, Woods R, Singer J, et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS 2011; 25:731-9; PMID:21330911; http://dx.doi.org/10.1097/ QAD.0b013e328344cea5
132. Lévy Y, Durier C, Lascaux AS, Meiffrédy V, Gahéry-Ségard H, Goujard C, et al & ANRS 093 Study Group. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-13; PMID:16439874; http://dx.doi.org/10.1097/01.aids.0000206504.09159.d3
133. Emery S, Kelleher AD, Workman C, Puls RL, Bloch M, Baker D, et al. Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum Vaccin 2007; 3:260-7; PMID:18340117
134. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schäfer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 1974; 99:2386-92; PMID:4426258; http://dx.doi.org/10.1055/s-0028-1108143
135. Ramírez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000; 74:923-33; PMID:10623755; http://dx.doi.org/10.1128/JVI.74.2.923-933.2000
136. Barouch DH, Santra S, Kuroda MJ, Schmitz JE, Plishka R, Buckler-White A, et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001; 75:5151-8; PMID:11333896; http://dx.doi.org/10.1128/JVI.75.11.5151-5158.2001
137. Ourmanov I, Brown CR, Moss B, Carroll M, Wyatt L, Pletneva L, et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000; 74:2740-51; PMID:10684290; http://dx.doi.org/10.1128/JVI.74.6.2740-2751.2000
138. Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76:7625-31; PMID:12097576; http://dx.doi.org/10.1128/JVI.76.15.7625-7631.2002
139. Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22:21-9; PMID:14604567; http://dx.doi.org/10.1016/S0264-410X(03)00538-3
140. Harrer E, Bäuerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005; 10:285-300; PMID:15865223
141. Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A, et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 2006; 80:4705-16; PMID:16641264; http://dx.doi.org/10.1128/JVI.80.10.4705-4716.2006
142. Ondondo BO, Yang H, Dong T, di Gleria K, Suttill A, Conlon C, et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 2006; 36:2585-94; PMID:17013989; http://dx.doi.org/10. 1002/eji.200636508
143. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, Conlon C, et al. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing anHIV-1 gag/ multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 2007; 25:3277-83; PMID:17257714; http://dx.doi.org/10.1016/j.vaccine.2007.01.005
144. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al & AIDS Clinical Trials Group 5197 Study Team. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010; 202:705-16; PMID: 20662716; http://dx.doi.org/10. 1086/655468
145. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, et al & AIDS Clinical Trials Group A5197 Study Team. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 2011; 203:976-83; PMID:21402549; http://dx.doi.org/10.1093/infdis/jiq143
146. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588
147. Bottomly K. T cells and dendritic cells get intimate. Science 1999; 283:1124-5; PMID:10075571; http://dx.doi.org/10.1126/science.283.5405.1124
148. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995; 267:243-6; PMID:7809629; http://dx.doi.org/10.1126/science.7809629
149. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17:131-7; PMID:8820271; http://dx.doi.org/10.1016/ 0167-5699(96)80605-0
150. Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 1996; 156:3721-6; PMID:8621907
151. Peters JH, Gieseler R, Thiele B, Steinbach F. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol Today 1996; 17:273-8; PMID: 8962630; http://dx.doi.org/10.1016/0167-5699(96)80544-5
152. Fan Z, Huang XL, Zheng L, Wilson C, Borowski L, Liebmann J, et al. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection. J Immunol 1997; 159:4973-82; PMID:9366424
153. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283:1183-6; PMID:10024247; http://dx.doi.org/10. 1126/science.283.5405.1183
154. Filgueira L, Nestlé FO, Rittig M, Joller HI, Groscurth P. Human dendritic cells phagocytose and process Borrelia burgdorferi. J Immunol 1996; 157:2998-3005; PMID:8816408
155. Mbow ML, Zeidner N, Panella N, Titus RG, Piesman J. Borrelia burgdorferi-pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes. Infect Immun 1997; 65:3386-90; PMID: 9234802
156. Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med 1998; 188:809-18; PMID:9730883; http://dx.doi.org/10.1084/jem.188.5.809
157. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1997; 158:3270-6; PMID:9120283
158. Svensson M, Stockinger B, Wick MJ. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol 1997; 158:4229-36; PMID:9126984
159. Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003; 9:27-32; PMID:12496959; http://dx.doi.org/10. 1038/nm806
160. Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T, et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 2003; 198:361-7; PMID:12874266; http://dx.doi.org/10.1084/jem.20021924
161. Yoshida A, Tanaka R, Murakami T, Takahashi Y, Koyanagi Y, Nakamura M, et al. Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-cell origin. J Virol 2003; 77:8719-28; PMID:12885891; http://dx.doi.org/10.1128/JVI.77.16.8719-8728.2003
162. Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses 1998; 14:551-60; PMID: 9591709; http://dx.doi.org/10.1089/aid.1998.14.551
163. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-65; PMID: 15568033; http://dx.doi.org/10.1038/nm1147
164. García F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J Infect Dis 2005; 195:1680-5; http://dx.doi.org/10.1086/429340
165. Ide F, Nakamura T, Tomizawa M, Kawana-Tachikawa A, Odawara T, Hosoya N, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol 2006; 78:711-8; PMID:16628588; http://dx.doi.org/10.1002/jmv.20612
166. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008; 15:284-92; PMID:17942609; http://dx.doi.org/10.1128/CVI.00221-07
167. Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, et al & AIDS Clinical Trials Group A5130 team. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009; 27:6088-94; PMID:19450647; http://dx.doi.org/10.1016/j.vaccine.2009.05.016
168. Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009; 23:1329-40; PMID:19528789; http://dx.doi.org/10.1097/QAD.0b013e32832d9b00
169. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134:140-7; PMID:19889582; http://dx.doi.org/10.1016/j.clim. 2009.09.009
170. García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, et al & DCV2/MANON07- AIDS Vaccine Research Objective Study Group. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011; 203:473-8; PMID:21233310; http://dx.doi.org/10.1093/infdis/jiq077
171. Routy JP, Angel J, Vezina S, Tremblay C, Loutfy M, Gill J, et al. Final Analysis of a Phase 2 Study of an Autologous DC Immunotherapy (AGS-004) Showed Positive Outcomes in Primary Endpoint of Viral Load Control, and Favorable Safety and Immunogenicity Profile, in Subjects Undergoing Structured Treatment Interruption of ART (Abstract 385) [Abstract]. 18th Conference on Retroviruses and Opportunistic Infections Boston February 27-March 2 2011.
172. García F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011; 29:6454-63; PMID:21791232